Diclofenamide: Difference between revisions
No edit summary |
No edit summary |
||
Line 29: | Line 29: | ||
Potassium excretion is increased by DARANIDE (dichlorphenamide tablets USP) and [[hypokalemia]] may develop. | Potassium excretion is increased by DARANIDE (dichlorphenamide tablets USP) and [[hypokalemia]] may develop. | ||
Interference with adequate oral electrolyte intake will also contribute to [[hypokalemia]]. [[Hypokalemia]] can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased [[ventricular irritability]]). [[Hypokalemia]] may be avoided or treated by use of potassium supplements such as foods with a high potassium content. | Interference with adequate oral electrolyte intake will also contribute to [[hypokalemia]]. [[Hypokalemia]] can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased [[ventricular irritability]]). [[Hypokalemia]] may be avoided or treated by use of potassium supplements such as foods with a high potassium content. | ||
|clinicalTrials=The most common adverse reactions include gastrointestinal disturbances ([[anorexia]], [[nausea]], and [[vomiting]]), [[drowsiness]] and [[paresthesias]]. | |||
Certain adverse reactions characteristic of carbonic anhydrase inhibitors may result with DARANIDE® (dichlorphenamide tablets USP), particularly with increasing doses. The following are adverse reactions which have been reported with systemic carbonic anhydrase inhibitors. The pharmacological similarities among the carbonic anhydrase inhibitors make it advisable to consider the following reactions when dichlorphenamide is administered: [[agranulocytosis]], [[ataxia]], [[confusion]], [[constipation]], [[depression]], [[disorientation]], [[dizziness]], electrolyte imbalance ([[hypokalemia]], [[hyperchloremia]]), [[fever]], [[globus hystericus]], [[headache]], [[hepatic insufficiency]], [[hyperuricemia]], kidney stones, [[lassitude]], [[leucopenia]], [[metabolic acidosis]], [[nervousness]], [[phosphaturia]], [[pruritus]], renal colic, [[skin eruptions]], [[thrombocytopenia]], [[tinnitus]], [[tremor]], urinary frequency, weakness, and weight loss. | |||
|drugInteractions=* High-dose Aspirin | |||
:* [[Anorexia]], [[tachypnea]], [[lethargy]] and [[coma]] have been rarely reported due to a possible drug interaction with high-dose [[aspirin]]. | |||
|FDAPregCat=C | |||
|useInPregnancyFDA=Pregnancy Category C. Dichlorphenamide has been shown to be teratogenic in the rat (skeletal anomalies) when given in doses 100 times the human dose. There are no adequate and well-controlled studies in pregnant women. DARANIDE® (dichlorphenamide tablets USP) should not be used in women of childbearing age or in pregnancy, especially during the first trimester, unless the potential benefits outweigh the potential risks. | |||
|useInNursing=It is not known whether dichlorphenamide is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dichlorphenamide is administered to a nursing woman. | |||
|useInPed=Safety and effectiveness in pediatric patients have not been established. | |||
|useInGeri=Metabolic acidosis, which can be severe, may occur in the elderly with reduced renal function. | |||
}} | }} |
Revision as of 13:04, 23 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Diclofenamide is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of elevated intraoculr pressure. Common adverse reactions include anorexia, nausea, vomiting, drowsiness, paresthesias..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Elevated Intraoculr Pressure
- Dosing Information
- Recommended initial dosage: 100-200 mg PO bid
- Recommended maintenence dosage: 25-50 mg PO qd or bid or tid
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Diclofenamide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
- DARANIDE® (dichlorphenamide tablets USP) is contraindicated in hepatic insufficiency.
- Electrolyte Imbalance
- DARANIDE® is contraindicated in renal failure, adrenocortical insufficiency, hyperchloremic acidosis, or in conditions in which serum levels of sodium or potassium are depressed.
- Obstructive Pulmonary Disease
- DARANIDE should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation since their acidosis may be increased.
- DARANIDE® is contraindicated in patients who are hypersensitive to this product.
Warnings
Hypokalemia
Potassium excretion is increased by DARANIDE (dichlorphenamide tablets USP) and hypokalemia may develop. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium supplements such as foods with a high potassium content.
Adverse Reactions
Clinical Trials Experience
The most common adverse reactions include gastrointestinal disturbances (anorexia, nausea, and vomiting), drowsiness and paresthesias. Certain adverse reactions characteristic of carbonic anhydrase inhibitors may result with DARANIDE® (dichlorphenamide tablets USP), particularly with increasing doses. The following are adverse reactions which have been reported with systemic carbonic anhydrase inhibitors. The pharmacological similarities among the carbonic anhydrase inhibitors make it advisable to consider the following reactions when dichlorphenamide is administered: agranulocytosis, ataxia, confusion, constipation, depression, disorientation, dizziness, electrolyte imbalance (hypokalemia, hyperchloremia), fever, globus hystericus, headache, hepatic insufficiency, hyperuricemia, kidney stones, lassitude, leucopenia, metabolic acidosis, nervousness, phosphaturia, pruritus, renal colic, skin eruptions, thrombocytopenia, tinnitus, tremor, urinary frequency, weakness, and weight loss.
Postmarketing Experience
There is limited information regarding Diclofenamide Postmarketing Experience in the drug label.
Drug Interactions
- High-dose Aspirin
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA): C
Pregnancy Category C. Dichlorphenamide has been shown to be teratogenic in the rat (skeletal anomalies) when given in doses 100 times the human dose. There are no adequate and well-controlled studies in pregnant women. DARANIDE® (dichlorphenamide tablets USP) should not be used in women of childbearing age or in pregnancy, especially during the first trimester, unless the potential benefits outweigh the potential risks.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Diclofenamide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Diclofenamide during labor and delivery.
Nursing Mothers
It is not known whether dichlorphenamide is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dichlorphenamide is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatic Use
Metabolic acidosis, which can be severe, may occur in the elderly with reduced renal function.
Gender
There is no FDA guidance on the use of Diclofenamide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Diclofenamide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Diclofenamide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Diclofenamide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Diclofenamide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Diclofenamide in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Diclofenamide Administration in the drug label.
Monitoring
There is limited information regarding Diclofenamide Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Diclofenamide and IV administrations.
Overdosage
There is limited information regarding Diclofenamide overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Diclofenamide Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Diclofenamide Mechanism of Action in the drug label.
Structure
There is limited information regarding Diclofenamide Structure in the drug label.
Pharmacodynamics
There is limited information regarding Diclofenamide Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Diclofenamide Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Diclofenamide Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Diclofenamide Clinical Studies in the drug label.
How Supplied
There is limited information regarding Diclofenamide How Supplied in the drug label.
Storage
There is limited information regarding Diclofenamide Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Diclofenamide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Diclofenamide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Diclofenamide Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Diclofenamide interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Diclofenamide Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Diclofenamide Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.